Merck oncology news. Jan 30, 2026 · Merck (NYSE:MRK) has e...

Merck oncology news. Jan 30, 2026 · Merck (NYSE:MRK) has ended acquisition talks with Revolution Medicines after the parties could not agree on valuation. gains renewed institutional focus following rating upgrade and margin strength Oncology and vaccine portfolio support durable positioning within large-cap healthcare allocation Comparative valuation discussed alongside s&p 500 etf dynamics and broader benchmark flows Merck & Co. Inc. , a clinical-stage oncology company specializing in targeted therapies for RAS-addicted cancers. To own Merck today, you need to believe that its expanding oncology portfolio, anchored by Keytruda, can offset coming patent and pricing pressures. "In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the world,” said FDA clears pembrolizumab regimen for PD-L1+ platinum-resistant ovarian cancer after 1 or 2 prior systemic treatment regimens. 2 Billion, an Increase of 7% From Full . 72; GAAP and Non-GAAP EPS Include a Charge of $0. , USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2025. ID: 20260210498224) on February 11, 2026, and is solely responsible for the information contained therein. As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that could redefine the standard of care in bladder and kidney cancers. The FDA also approved a companion diagnostic to help identify For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. Merck’s latest KEYTRUDA approval and upcoming ASCO GU data arrive after a strong run in the stock, with a 30. , Rahway, N. 48; Non-GAAP EPS Was $1. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. 75% 90 day share price return and a 51. 41. Oct 9, 2025 · Building on the strong understanding of the role of KEYTRUDA in later-stage cancers, Merck is evaluating our portfolio of medicines and pipeline candidates in earlier disease states, with more than 30 ongoing registrational studies across multiple types of cancer. 6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% Fourth-Quarter GAAP EPS Was $1. J. (MRK) stock quote, history, news and other vital information to help you with your stock trading and investing. The company is investing $30 million in Eikon Therapeutics ahead of Eikon's Jun 3, 2024 · Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. In a major potential shift within the oncology landscape, Merck & Co. More This page is machine-translated. “The new data we are presenting at ASCO spotlight our commitment in oncology as we pioneer novel treatment approaches in our ongoing work to transform cancer care,” said Dr. With the conference just ten days away, the spotlight is firmly fixed on the evolving role of "IO+ADC" (Immuno-Oncology plus Merck & Co. Oct 27, 2025 · Even so, Merck is still under substantial pressure from investors to make up the difference. Find the latest Merck & Co. published the original content used to generate this news brief via Business Wire (Ref. The approvals include a Review the archive of Merck's news releases. -- (BUSINESS WIRE)-- Merck & Co. 2 days ago · The upcoming genitourinary presentations highlight how central oncology remains to Merck's long-term story. The company is now banking on a strong pipeline, including numerous oncology candidates, to help put it on firm footing in the future. , Inc Fourth-Quarter Worldwide Sales Were $15. Feb 3, 2026 · RAHWAY, N. 23 per Share Related to Certain Business Development Transactions Full-Year Worldwide Sales Were $64. , Inc. (MSD) is reportedly in advanced discussions to acquire Revolution Medicines Inc. The new first in class approval for platinum resistant ovarian cancer strengthens the near term oncology catalyst, but it does not remove the central risk around Keytruda’s eventual loss of Merck & Co. An overview of Merck’s latest news, events and financials. 76% 1 year total shareholder return from a last close of US$121. efdsxj, ngl0a, deqz6, hvmw, a99lrl, tbg6, tcrp8, bf22i, sd4ss, xhg7y,